

SAFETY INSPECTION REPORT
AND COMPLIANCE INSPECTION

| | | | |
|--|--|--|--|
| 1. LICENSEE Terre Haute Regional Hospital REPORT NUMBER(S) 2008-01 | | 2. NRC/REGIONAL OFFICE Region III 2443 Warrenville Road, Suite 210 Lisle, IL 60532 | |
| 3. DOCKET NUMBER(S) 03009540 | 4. LICENSE NUMBER(S) 13-09649-02 | 5. DATE(S) OF INSPECTION July 29, 2008 | |
| 6. INSPECTION PROCEDURES USED 87131 | | 7. INSPECTION FOCUS AREAS 03.01-03.07 | |

SUPPLEMENTAL INSPECTION INFORMATION

| | | | |
|-----------------------------------|--------------------------|---|--|
| 1. PROGRAM CODE(S) 2120 | 2. PRIORITY G3 | 3. LICENSEE CONTACT Edward Johnston III., RSO | 4. TELEPHONE NUMBER 812-232-0021 |
|-----------------------------------|--------------------------|---|--|

| | |
|--|--------------------------------------|
| <input checked="" type="checkbox"/> Main Office Inspection | Next Inspection Date: 08/2011 |
| <input type="checkbox"/> Field Office | |
| <input type="checkbox"/> Temporary Job Site Inspection | |

PROGRAM SCOPE

This active medical facility performs about 120 diagnostic nuclear medicine procedures monthly. No Mo/Tc99m Generators are received and licensed material is obtain as unit doses through an area nuclear pharmacy. Two full-time technologists are responsible for daily patient imaging, etc. Approximately 6 lung ventilations are performed monthly using xenon-133 and Tc99m DTPA aerosol each.

The licensee's iodine-131 program consists of treatments for hyperthyroidism and about five thyroid ablation treatments annually both in capsule form.

The licensee's conventional brachytherapy program is limited to approximately six ultrasound guided iodine-125 prostate seed implants annually and approximately two temporary implant treatments annually utilizing cesium-137. Iridium-192 is not currently used.

Performance Observations

Interviews conducted with available nuclear medicine staff revealed an adequate level of understanding of emergency and material handling procedures and techniques. Patient injections observed included the use of gloves, personnel dosimetry, syringe shields and proper clothing. Area surveys, package surveys and wipes and dose calibrator constancy checks were demonstrated with no problems noted. Quarterly compliance audits are performed by a consultant physicist and appear to adequately oversee licensed activities.

A random review of radiopharmaceutical and brachytherapy implant written directives included all required information and did not reveal medical or recordable events. Sealed source accountability and leak tests were also well maintained and did not reveal inventory discrepancies or contamination. Cesium-137 brachytherapy sources are leak tested each three years.

Personal dosimetry records were reviewed for 2007 revealed whole-body and extremity readings of 230 mRem and 1250 mRem respectively. YTD 2008 whole-body and extremity readings indicated 98 mRem and 420 mRem respectively.

Overall, licensed material was observed under surveillance during the review and was not readily accessible to members of the general public. Independent measurements taken in restricted and/or unrestricted areas of nuclear medicine and the brachytherapy storage area did not indicate readings above expected.